Elan to sell remaining ordinary shares of Alkermes
The firm is planning to sell the shares through its wholly-owned subsidiary Elan Science Three and is expected to close the deal on 6 February 2013. Elan through
Ultragenyx Pharmaceutical has received accelerated approval from the US Food and Drug Administration (FDA) for its gene therapy, Genglycos (pariglasgene brecaparvovec-opnr), to treat glycogen storage disease type Ia (GSDIa).
Cetac is involved in providing sample handling and introduction products including autosamplers, autodilutors, liquid handling platforms and sample preparation stations to pharmaceutical, life sciences, clinical/forensic and separation sciences,
Auvi-Q (epinephrine injection), which the company claims is the first-and-only epinephrine auto-injector with audio and visual cues, features an automatic retractable needle mechanism to help prevent accidental needle